Latest news with #ProteomicsInternational
Sydney Morning Herald
14-07-2025
- Health
- Sydney Morning Herald
Proteomics streaks ahead with simple test for injured racehorses
Proteomics International is on track to deliver a world-first simple blood test in Australia this year to detect muscle damage in thoroughbred horses, which could revolutionise the way injuries are detected and monitored after a race. The company's 66 per cent-owned subsidiary OxiDx Limited has developed the blood test technology alongside researchers at The University of Western Australia. It uses a drop of dried blood to test for two protein biomarkers, which can identify the level of muscle damage in horses. Proteomics aims to launch the first-in-class OxiDx test in Australia this year, and then plans to expand into the United States via the company's accredited Californian reference laboratory. The company also has a clinical study underway to validate OxiDx's ability to predict muscle damage in racehorses, which will further support its commercialisation efforts. Proteomics says the test will offer trainers a simple way to objectively measure a horse's muscle injury recovery, allowing them to tailor training and racing schedules to optimise the animal's post-race recovery and potentially enhance their subsequent performance. 'OxiDx has the potential to empower trainers to monitor muscle recovery with precision, helping their racehorses achieve peak performance while prioritising equine health and well-being.' Proteomics International managing director Dr Richard Lipscombe Over the weekend, the company published the results of a study of the novel test in the peer-reviewed journal, Veterinary Medicine and Science, which showed its OxiDx oxidative stress tests could monitor muscle recovery in racehorses. Oxidative stress is caused by an overload of toxic oxidants - known as free radicals - which can overpower the body's natural defences, throwing the system off balance. For the study, a group of Australian trainers collected dried blood samples from 34 horses before and up to seven days post-race, which were analysed by an external pathology centre for two key protein biomarkers.
The Age
14-07-2025
- Health
- The Age
Proteomics streaks ahead with simple test for injured racehorses
Proteomics International is on track to deliver a world-first simple blood test in Australia this year to detect muscle damage in thoroughbred horses, which could revolutionise the way injuries are detected and monitored after a race. The company's 66 per cent-owned subsidiary OxiDx Limited has developed the blood test technology alongside researchers at The University of Western Australia. It uses a drop of dried blood to test for two protein biomarkers, which can identify the level of muscle damage in horses. Proteomics aims to launch the first-in-class OxiDx test in Australia this year, and then plans to expand into the United States via the company's accredited Californian reference laboratory. The company also has a clinical study underway to validate OxiDx's ability to predict muscle damage in racehorses, which will further support its commercialisation efforts. Proteomics says the test will offer trainers a simple way to objectively measure a horse's muscle injury recovery, allowing them to tailor training and racing schedules to optimise the animal's post-race recovery and potentially enhance their subsequent performance. 'OxiDx has the potential to empower trainers to monitor muscle recovery with precision, helping their racehorses achieve peak performance while prioritising equine health and well-being.' Proteomics International managing director Dr Richard Lipscombe Over the weekend, the company published the results of a study of the novel test in the peer-reviewed journal, Veterinary Medicine and Science, which showed its OxiDx oxidative stress tests could monitor muscle recovery in racehorses. Oxidative stress is caused by an overload of toxic oxidants - known as free radicals - which can overpower the body's natural defences, throwing the system off balance. For the study, a group of Australian trainers collected dried blood samples from 34 horses before and up to seven days post-race, which were analysed by an external pathology centre for two key protein biomarkers.
The Age
03-07-2025
- Health
- The Age
Protoemics diabetes test gets important US health insurance nod
Proteomics International is on the verge of releasing its groundbreaking PromarkerD diabetes-related blood test across the United States, a milestone step ahead the device's international commercialisation. PromarkerD has just been assigned an American Medical Association PLA billing code, required for doctors to order the test and for facilities to bill for its use. From October 1, patients and healthcare providers will be able to submit claims for the test to be reimbursed by their health insurers – an essential step towards a broader market uptake. PromarkerD was designed to meet an area of unmet need by identifying diabetic patients at risk of developing kidney disease four years before any symptoms appear. According to the company's latest clinical study, its patented next-generation PromarkerD test accurately predicted kidney function decline in up to 86 per cent of patients who otherwise showed no symptoms, replicating the results from earlier clinical trials. 'Ensuring kidney health is a priority for our company and obtaining this dedicated PLA code is a crucial milestone in our strategy to improve access to meaningful diagnostic tests.' Proteomics International managing director Dr Richard Lipscombe Catching early signs of diabetic kidney disease means patients can receive preventive care well before they develop costly and life-threatening end-stage kidney disease, avoiding the need for dialysis or a kidney transplant. The simple finger-prick blood test could potentially throw a lifeline to more than 32 million Americans living with type 2 diabetes, given more than half of all adults with diabetes in the US will develop kidney complications. These cases contribute to a colossal US$130 billion in annual healthcare costs - more than a quarter of the nation's Medicare budget. Proteomics International managing director Dr Richard Lipscombe said: 'Ensuring kidney health is a priority for our company and obtaining this dedicated PLA code is a crucial milestone in our strategy to improve access to meaningful diagnostic tests. Expanding access to PromarkerD will help to improve kidney health for patients everywhere.' The PLA code is widely used across America's complex health insurance system to report the use of medical procedures and services. It also allows insurers to monitor their use.
Sydney Morning Herald
03-07-2025
- Health
- Sydney Morning Herald
Protoemics diabetes test gets important US health insurance nod
Proteomics International is on the verge of releasing its groundbreaking PromarkerD diabetes-related blood test across the United States, a milestone step ahead the device's international commercialisation. PromarkerD has just been assigned an American Medical Association PLA billing code, required for doctors to order the test and for facilities to bill for its use. From October 1, patients and healthcare providers will be able to submit claims for the test to be reimbursed by their health insurers – an essential step towards a broader market uptake. PromarkerD was designed to meet an area of unmet need by identifying diabetic patients at risk of developing kidney disease four years before any symptoms appear. According to the company's latest clinical study, its patented next-generation PromarkerD test accurately predicted kidney function decline in up to 86 per cent of patients who otherwise showed no symptoms, replicating the results from earlier clinical trials. 'Ensuring kidney health is a priority for our company and obtaining this dedicated PLA code is a crucial milestone in our strategy to improve access to meaningful diagnostic tests.' Proteomics International managing director Dr Richard Lipscombe Catching early signs of diabetic kidney disease means patients can receive preventive care well before they develop costly and life-threatening end-stage kidney disease, avoiding the need for dialysis or a kidney transplant. The simple finger-prick blood test could potentially throw a lifeline to more than 32 million Americans living with type 2 diabetes, given more than half of all adults with diabetes in the US will develop kidney complications. These cases contribute to a colossal US$130 billion in annual healthcare costs - more than a quarter of the nation's Medicare budget. Proteomics International managing director Dr Richard Lipscombe said: 'Ensuring kidney health is a priority for our company and obtaining this dedicated PLA code is a crucial milestone in our strategy to improve access to meaningful diagnostic tests. Expanding access to PromarkerD will help to improve kidney health for patients everywhere.' The PLA code is widely used across America's complex health insurance system to report the use of medical procedures and services. It also allows insurers to monitor their use.
The Age
01-07-2025
- Business
- The Age
$6M boost to drive industrial-scale Proteomics facility in WA
Proteomics International will expand its Perth facility into a national diagnostics hub using a $6 million funding boost to develop a new protein biomarker analysis platform for industrial-scale precision medical and agricultural screening. The company will partner with The University of Western Australia (UWA), the Western Australian Government and life science research collaborator BioPlatforms Australia to develop its world-class Perth facility. The partners want to target a growing market for high-throughput precision diagnostics across medicine and agriculture. Proteomics and UWA will each kick $1 million into the kitty for the three-year project to develop an accredited protein biomarker analysis platform capable of helping push advances in the two critical sectors. The Proteomics and UWA laboratories collaborate to bring together scientific and technological know-how to tease out the answers to everyday problems in health, agriculture and environmental sciences respectively, focusing on the emerging proteomics field. Proteomics researchers work on identifying and measuring the changes in proteins within cells. Unlike DNA, proteins can change - studying them allows scientists to develop diagnostic tests that can detect diseases earlier and allow doctors to tailor treatments to their patients. 'This facility can become a national hub for precision diagnostic testing across clinical and agricultural proteomics.' Proteomics International managing director Dr Richard Lipscombe In agriculture, it could be used to guide grain selection or sowing decisions to improve yield and sustainability, for example. This may become particularly significant given the world's growing population and drying climate, which means farmers must increasingly work to maximise yields while they safeguard crops against drought, salinity, weeds and pests. Proteomics International managing director Dr Richard Lipscombe said: 'This facility can become a national hub for precision diagnostic testing across clinical and agricultural proteomics. Extending our recent successful capital raise with state-of-the-art infrastructure to analyse thousands of samples at industrial scale, we can turn biological insight into real-world solutions - whether that's improving outcomes for patients with chronic diseases or selecting better crop varieties to address food security.' Proteomics says achieving a new nationally accredited technology platform would significantly boost the facility's capacity for fast and accurate screening, help roll out diagnostic tests for clinical use and enable it to test large sets of agricultural and environmental samples.
